Latest Breaking News On - Phospholipid drug conjugate - Page 2 : comparemela.com

Cellectar Biosciences to Present at the Oppenheimer 34th

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused.

Cellectar biosciencesJames carusoClaire lacagninaBliss bio healthCellectar biosciences incHealthcare life sciences conferenceAnnual healthcare life sciences conferencePhospholipid drug conjugateNasdaq clrbCellectar biosciences

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James carusoCellectar biosciencesHealthcare life sciences conferenceCellectar biosciences incClaire lacagninabliss bio healthAnnual healthcare life sciences conferenceInc cellectar biosciencesPhospholipid drug conjugateChad koleanchief financial

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

FLORHAM PARK, N.J., Jan. 30, 2024 Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the.

United statesSameer farouk saitJames carusoClaire lacagninaCellectar biosciencesExchange commissionNational cancer instituteGlobenewswire incBliss bio healthCellectar biosciences incMemorial sloan kettering cancer centerNational institute of healthFarouk saitSloan kettering cancerBing neel syndromeFast track

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44 1 Million

FLORHAM PARK, N.J., Jan. 25, 2024 Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the.

United statesCellectar biosciencesJames carusoClaire lacagninaExchange commissionCellectar biosciences incGlobenewswire incBliss bio healthNew drug applicationPhospholipid drug conjugate

Cellectar Biosciences Reports Complete Central Nervous

Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development.

United statesAndrei shustovWaldenstrom macroglobulinemiaJorge castilloCellectar biosciencesClaire lacagninaExchange commissionHarvard medical schoolNational institute of health cancerBliss bio healthCellectar biosciences incBing neel syndromeBing center clinicDana farber cancerNational instituteNational cancer institute